<VariationArchive VariationID="265543" VariationName="NM_004360.5(CDH1):c.1354_1357del (p.Leu452fs)" VariationType="Deletion" Accession="VCV000265543" Version="15" RecordType="classified" NumberOfSubmissions="6" NumberOfSubmitters="6" DateLastUpdated="2024-07-15" DateCreated="2016-10-10" MostRecentSubmission="2024-06-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="260123" VariationID="265543">
      <GeneList>
        <Gene Symbol="CDH1" FullName="cadherin 1" GeneID="999" HGNC_ID="HGNC:1748" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16q22.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="68737292" stop="68835537" display_start="68737292" display_stop="68835537" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="68771194" stop="68869443" display_start="68771194" display_stop="68869443" Strand="+" />
          </Location>
          <OMIM>192090</OMIM>
          <Haploinsufficiency last_evaluated="2020-04-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CDH1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-04-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CDH1">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_004360.5(CDH1):c.1354_1357del (p.Leu452fs)</Name>
      <CanonicalSPDI>NC_000016.10:68815547:CTAC:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16q22.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="68815548" stop="68815551" display_start="68815548" display_stop="68815551" variantLength="4" positionVCF="68815547" referenceAlleleVCF="TCTAC" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="68849451" stop="68849454" display_start="68849451" display_stop="68849454" variantLength="4" positionVCF="68849450" referenceAlleleVCF="TCTAC" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>L391fs</ProteinChange>
      <ProteinChange>L452fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_301" sequenceAccession="LRG_301" change="g.83257_83260del">
            <Expression>LRG_301:g.83257_83260del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_301t1" sequenceAccession="LRG_301t1" change="c.1354_1357del">
            <Expression>LRG_301t1:c.1354_1357del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.10" sequenceAccession="NC_000016" sequenceVersion="10" change="g.68815548_68815551del" Assembly="GRCh38">
            <Expression>NC_000016.10:g.68815548_68815551del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.68849451_68849454del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.68849451_68849454del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008021.1" sequenceAccession="NG_008021" sequenceVersion="1" change="g.83257_83260del">
            <Expression>NG_008021.1:g.83257_83260del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001317184.2" sequenceAccession="NM_001317184" sequenceVersion="2" change="c.1171_1174del">
            <Expression>NM_001317184.2:c.1171_1174del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001304113.1" sequenceAccession="NP_001304113" sequenceVersion="1" change="p.Leu391fs">
            <Expression>NP_001304113.1:p.Leu391fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001317185.2" sequenceAccession="NM_001317185" sequenceVersion="2" change="c.-195_-192del">
            <Expression>NM_001317185.2:c.-195_-192del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001317186.2" sequenceAccession="NM_001317186" sequenceVersion="2" change="c.-466_-463del">
            <Expression>NM_001317186.2:c.-466_-463del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004360.5" sequenceAccession="NM_004360" sequenceVersion="5" change="c.1354_1357del" MANESelect="true">
            <Expression>NM_004360.5:c.1354_1357del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_004351.1" sequenceAccession="NP_004351" sequenceVersion="1" change="p.Leu452fs">
            <Expression>NP_004351.1:p.Leu452fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004360.5" sequenceAccession="NM_004360" sequenceVersion="5" change="c.1354_1357del" MANESelect="true">
            <Expression>NM_004360.5(CDH1):c.1354_1357del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA10588623" DB="ClinGen" />
        <XRef Type="rs" ID="886039612" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_004360.5(CDH1):c.1354_1357del (p.Leu452fs) AND not provided" Accession="RCV000256004" Version="4">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2017-11-20" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004360.5(CDH1):c.1354_1357del (p.Leu452fs) AND Hereditary diffuse gastric adenocarcinoma" Accession="RCV001195174" Version="10">
        <ClassifiedConditionList TraitSetID="3314">
          <ClassifiedCondition DB="MedGen" ID="C1708349">Hereditary diffuse gastric adenocarcinoma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-06-13" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004360.5(CDH1):c.1354_1357del (p.Leu452fs) AND multiple conditions" Accession="RCV002494804" Version="4">
        <ClassifiedConditionList TraitSetID="40855">
          <ClassifiedCondition DB="MedGen" ID="C4551988">Blepharocheilodontic syndrome 1</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0476089">Endometrial carcinoma</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0346153">Familial cancer of breast</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1708349">Hereditary diffuse gastric adenocarcinoma</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0376358">Malignant tumor of prostate</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0919267">Ovarian neoplasm</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-12-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004360.5(CDH1):c.1354_1357del (p.Leu452fs) AND CDH1-related diffuse gastric and lobular breast cancer syndrome" Accession="RCV003328316" Version="3">
        <ClassifiedConditionList TraitSetID="86761">
          <ClassifiedCondition DB="MedGen" ID="CN311521">CDH1-related diffuse gastric and lobular breast cancer syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>reviewed by expert panel</ReviewStatus>
            <Description DateLastEvaluated="2023-08-04" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004360.5(CDH1):c.1354_1357del (p.Leu452fs) AND Familial cancer of breast" Accession="RCV004567810" Version="1">
        <ClassifiedConditionList TraitSetID="774">
          <ClassifiedCondition DB="MedGen" ID="C0346153">Familial cancer of breast</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-12-22" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-08-04" NumberOfSubmissions="6" NumberOfSubmitters="6" DateCreated="2016-10-10" MostRecentSubmission="2024-06-17">
        <ReviewStatus>reviewed by expert panel</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">15235021</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20373070</ID>
        </Citation>
        <Citation Type="general">
          <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/9d69b4f3-8f18-42f4-9ad0-719f091202ce</URL>
        </Citation>
        <DescriptionHistory Dated="2021-09-29">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="40855" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="1360" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hereditary diffuse gastric adenocarcinoma</ElementValue>
                <XRef ID="MONDO:0007648" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary diffuse gastric cancer</ElementValue>
                <XRef ID="Hereditary+diffuse+gastric+cancer/8514" DB="Genetic Alliance" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">HDGC</ElementValue>
                <XRef Type="MIM" ID="137215" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10900" />
                <XRef ID="10900" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant susceptibility for diffuse gastric cancer, a poorly differentiated adenocarcinoma that infiltrates into the stomach wall causing thickening of the wall (linitis plastica) without forming a distinct mass. Diffuse gastric cancer is also referred to as signet ring carcinoma or isolated cell-type carcinoma. The average age of onset of HDGC is 38 years (range: 14-69 years). The majority of the cancers in individuals with a CDH1 pathogenic variant occur before age 40 years. The estimated cumulative risk of gastric cancer by age 80 years is 70% for men and 56% for women. Women are also at a 42% risk for lobular breast cancer.</Attribute>
                <XRef ID="NBK1139" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301318</ID>
                <ID Source="BookShelf">NBK1139</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="IGCLC, 2010">
                <ID Source="pmc">2991043</ID>
              </Citation>
              <Citation Type="general" Abbrev="Klujit et al., 2012">
                <ID Source="PubMed">22388873</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACG, 2015">
                <ID Source="PubMed">25645574</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="IGCLC, 2020">
                <ID Source="PubMed">32758476</ID>
                <ID Source="pmc">7116190</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Gastric Cancer, 2023</CitationText>
              </Citation>
              <XRef ID="26106" DB="Orphanet" />
              <XRef ID="C1708349" DB="MedGen" />
              <XRef ID="MONDO:0007648" DB="MONDO" />
              <XRef Type="MIM" ID="137215" DB="OMIM" />
            </Trait>
            <Trait ID="536" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Familial cancer of breast</ElementValue>
                <XRef ID="Familial+cancer+of+breast/8375" DB="Genetic Alliance" />
                <XRef ID="254843006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17142" />
                <XRef ID="17142" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000561700" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="St. Gallen, 2021">
                <ID Source="PubMed">34242744</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="227535" DB="Orphanet" />
              <XRef ID="C0346153" DB="MedGen" />
              <XRef ID="MONDO:0016419" DB="MONDO" />
              <XRef Type="MIM" ID="114480" DB="OMIM" />
            </Trait>
            <Trait ID="1151" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Endometrial carcinoma</ElementValue>
                <XRef ID="Endometrial+cancer/8312" DB="Genetic Alliance" />
                <XRef ID="HP:0012114" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0002447" DB="MONDO" />
                <XRef ID="254878006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Endometrial carcinoma, somatic</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="AHRQ, 2013">
                <URL>https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id90TA.pdf</URL>
                <CitationText>Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin (ARCHIVED)</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="SGO, 2014">
                <ID Source="PubMed">24905773</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="SGO, 2021">
                <ID Source="PubMed">33516529</ID>
              </Citation>
              <Citation Type="general" Abbrev="SGO, 2021">
                <ID Source="PubMed">33451724</ID>
              </Citation>
              <Citation Type="general" Abbrev="SGO, 2014">
                <ID Source="PubMed">24929052</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2020">
                <URL>https://www.nice.org.uk/guidance/dg42</URL>
                <CitationText>UK NICE Diagnostics Guidance DG42, Testing strategies for Lynch syndrome in people with endometrial cancer, 2020</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Uterine Neoplasms, 2024</CitationText>
              </Citation>
              <XRef ID="C0476089" DB="MedGen" />
              <XRef ID="MONDO:0002447" DB="MONDO" />
              <XRef Type="MIM" ID="608089" DB="OMIM" />
              <XRef Type="primary" ID="HP:0012114" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="5807" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Prostate cancer</ElementValue>
                <XRef ID="HP:0012125" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0008315" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Malignant tumor of prostate</ElementValue>
                <XRef ID="Prostate+cancer/9175" DB="Genetic Alliance" />
                <XRef ID="399068003" DB="SNOMED CT" />
              </Name>
              <Citation Type="general" Abbrev="NACB, 2008">
                <ID Source="PubMed">19042984</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGAPP, 2014">
                <ID Source="PubMed">24071797</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="NCCN, 2011">
                <ID Source="PubMed">22138009</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="AUA, 2018">
                <ID Source="PubMed">23659877</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Prostate cancer genetics">
                <ID Source="PubMed">26389227</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Prostate Cancer, 2024</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2021">
                <ID Source="PubMed">33497248</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2019">
                <ID Source="PubMed">31829902</ID>
              </Citation>
              <Citation Type="general" Abbrev="HKUA/HKSU-O, 2022">
                <ID Source="PubMed">35924163</ID>
                <ID Source="pmc">9339641</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/ng12</URL>
                <CitationText>UK NICE Guideline NG12, Suspected cancer: recognition and referral, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2021">
                <URL>https://www.nice.org.uk/guidance/ng131</URL>
                <CitationText>UK NICE Guideline NG131, Prostate cancer: diagnosis and management, 2021</CitationText>
              </Citation>
              <XRef ID="1331" DB="Orphanet" />
              <XRef ID="C0376358" DB="MedGen" />
              <XRef ID="MONDO:0008315" DB="MONDO" />
              <XRef Type="primary" ID="HP:0012125" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="5713" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Ovarian neoplasm</ElementValue>
                <XRef ID="HP:0100615" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0021068" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neoplasm of ovary</ElementValue>
                <XRef ID="123843001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ovarian Neoplasms</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ovarian tumor</ElementValue>
                <XRef ID="HP:0100615" DB="Human Phenotype Ontology" />
                <XRef ID="123843001" DB="SNOMED CT" />
              </Name>
              <Citation Type="general" Abbrev="NACB, 2008">
                <ID Source="PubMed">19042984</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2012">
                <ID Source="PubMed">22964825</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23188549</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2021">
                <ID Source="PubMed">33410258</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2018">
                <ID Source="PubMed">29450531</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg122</URL>
                <CitationText>UK NICE Clinical guideline (CG122), Ovarian cancer: recognition and initial management, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, 2024</CitationText>
              </Citation>
              <XRef ID="C0919267" DB="MedGen" />
              <XRef ID="D010051" DB="MeSH" />
              <XRef ID="MONDO:0021068" DB="MONDO" />
              <XRef Type="primary" ID="HP:0100615" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="1030" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Blepharocheilodontic syndrome 1</ElementValue>
                <XRef ID="MONDO:0054740" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">BCDS1</ElementValue>
                <XRef Type="MIM" ID="119580" DB="OMIM" />
              </Symbol>
              <XRef ID="1997" DB="Orphanet" />
              <XRef ID="C4551988" DB="MedGen" />
              <XRef ID="MONDO:0054740" DB="MONDO" />
              <XRef Type="MIM" ID="119580" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="3314" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="1360" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hereditary diffuse gastric adenocarcinoma</ElementValue>
                <XRef ID="MONDO:0007648" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary diffuse gastric cancer</ElementValue>
                <XRef ID="Hereditary+diffuse+gastric+cancer/8514" DB="Genetic Alliance" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">HDGC</ElementValue>
                <XRef Type="MIM" ID="137215" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10900" />
                <XRef ID="10900" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant susceptibility for diffuse gastric cancer, a poorly differentiated adenocarcinoma that infiltrates into the stomach wall causing thickening of the wall (linitis plastica) without forming a distinct mass. Diffuse gastric cancer is also referred to as signet ring carcinoma or isolated cell-type carcinoma. The average age of onset of HDGC is 38 years (range: 14-69 years). The majority of the cancers in individuals with a CDH1 pathogenic variant occur before age 40 years. The estimated cumulative risk of gastric cancer by age 80 years is 70% for men and 56% for women. Women are also at a 42% risk for lobular breast cancer.</Attribute>
                <XRef ID="NBK1139" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301318</ID>
                <ID Source="BookShelf">NBK1139</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="IGCLC, 2010">
                <ID Source="pmc">2991043</ID>
              </Citation>
              <Citation Type="general" Abbrev="Klujit et al., 2012">
                <ID Source="PubMed">22388873</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACG, 2015">
                <ID Source="PubMed">25645574</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="IGCLC, 2020">
                <ID Source="PubMed">32758476</ID>
                <ID Source="pmc">7116190</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Gastric Cancer, 2023</CitationText>
              </Citation>
              <XRef ID="26106" DB="Orphanet" />
              <XRef ID="C1708349" DB="MedGen" />
              <XRef ID="MONDO:0007648" DB="MONDO" />
              <XRef Type="MIM" ID="137215" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="774" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="536" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Familial cancer of breast</ElementValue>
                <XRef ID="Familial+cancer+of+breast/8375" DB="Genetic Alliance" />
                <XRef ID="254843006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17142" />
                <XRef ID="17142" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000561700" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="St. Gallen, 2021">
                <ID Source="PubMed">34242744</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="227535" DB="Orphanet" />
              <XRef ID="C0346153" DB="MedGen" />
              <XRef ID="MONDO:0016419" DB="MONDO" />
              <XRef Type="MIM" ID="114480" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="86761" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="62276" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">CDH1-related diffuse gastric and lobular breast cancer</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">CDH1-related diffuse gastric and lobular breast cancer syndrome</ElementValue>
                <XRef ID="MONDO:0100488" DB="MONDO" />
              </Name>
              <XRef ID="CN311521" DB="MedGen" />
              <XRef ID="MONDO:0100488" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="617176" SubmissionDate="2019-01-29" DateLastUpdated="2016-10-10" DateCreated="2016-10-10">
        <ClinVarSubmissionID localKey="GDX:831494|Not Provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000322523" DateUpdated="2016-10-10" DateCreated="2016-10-10" Type="SCV" Version="8" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-11-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>This deletion of four nucleotides in CDH1 is denoted c.1354_1357delCTAC at the cDNA level and p.Leu452ThrfsX2 (L452TfsX2) at the protein level. The normal sequence, with the bases that are deleted in brackets, is CATT[delCTAC]ACGT. The deletion causes a frameshift, which changes a Leucine to a Threonine at codon 452, and creates a premature stop codon at position 2 of the new reading frame. Although this variant has not, to our knowledge, been reported in the literature, it is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. Based on the currently available information, we consider this deletion to be a likely pathogenic variant.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification (06012015)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/dhtz9flo/genedx_interprules_final_061215.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CDH1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004360.3:c.1354_1357delCTAC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5098196</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5452048" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_004360.5:c.1354_1357del|OMIM:114480;119580;137215;167000;176807;608089" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002795430" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-12-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004360.5:c.1354_1357del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114480" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="119580" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="137215" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="167000" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="176807" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="608089" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion FDARecognizedDatabase="true" ID="2693347" SubmissionDate="2023-09-13" DateLastUpdated="2023-09-20" DateCreated="2020-07-04">
        <ClinVarSubmissionID localKey="9d69b4f3-8f18-42f4-9ad0-719f091202ce" localKeyIsSubmitted="1" submittedAssembly="not applicable" />
        <ClinVarAccession Accession="SCV001365461" DateUpdated="2023-09-20" DateCreated="2020-07-04" Type="SCV" Version="3" SubmitterName="ClinGen CDH1 Variant Curation Expert Panel" OrgID="506817" OrganizationCategory="consortium" OrgAbbreviation="CDH1 EP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-08-04">
          <ReviewStatus>reviewed by expert panel</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/9d69b4f3-8f18-42f4-9ad0-719f091202ce</URL>
          </Citation>
          <Comment>The c.1354_1357delCTAC p.(Leu452fs) variant is predicted to result in a premature stop codon that leads to nonsense mediate decay (PVS1 and PM5_supporting). The variant is absent in the gnomAD cohort (PM2_supporting; http://gnomad.broadinstitute.org). Therefore, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (CDH1 VCEP specifications version 3.1): PVS1, PM2_supporting, PM5_supporting.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ClinGen CDH1 ACMG Specifications V3.1</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/zeannmug/clingen_cdh1_acmg_specifications_v3.1.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CDH1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_004360.5(CDH1):c.1354_1357del</Name>
            <Name>p.Leu452fs</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.10:g.68815548_68815551del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0100488" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10433466</SubmissionName>
          <SubmissionName>SUB13838303</SubmissionName>
          <SubmissionName>SUB7564405</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3114235" SubmissionDate="2024-02-07" DateLastUpdated="2024-02-28" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="10280534|MedGen:C1708349" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001588574" DateUpdated="2024-02-28" DateCreated="2021-05-10" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-04-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15235021</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20373070</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 265543). This variant has not been reported in the literature in individuals affected with CDH1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Leu452Thrfs*2) in the CDH1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CDH1 are known to be pathogenic (PMID: 15235021, 20373070).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CDH1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.68849451_68849454del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1708349" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200269</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7568991" SubmissionDate="2023-10-23" DateLastUpdated="2023-10-28" DateCreated="2023-10-21">
        <ClinVarSubmissionID localKey="100199914|OMIM:137215" />
        <ClinVarAccession Accession="SCV004044122" DateUpdated="2023-10-28" DateCreated="2023-10-21" Type="SCV" Version="2" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-06-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Autosomal Dominant, Autosomal Recessive and X-Linked Classification Criteria (2023)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/8ufcwsf2/myriad_genetics_classification_criteria_2023.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CDH1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="hg19" Chr="16" alternateAllele="T" referenceAllele="TCTAC" start="68849450" stop="68849454" />
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">100199914</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="137215" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13911051</SubmissionName>
          <SubmissionName>SUB13922314</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9817076" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2024-06-17">
        <ClinVarSubmissionID localKey="NM_004360.5:c.1354_1357del|OMIM:114480" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV005060114" DateUpdated="2024-06-17" DateCreated="2024-06-17" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004360.5:c.1354_1357del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114480" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5452048" TraitType="Disease" MappingType="XRef" MappingValue="176807" MappingRef="OMIM">
        <MedGen CUI="C2931456" Name="Familial prostate carcinoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5452048" TraitType="Disease" MappingType="XRef" MappingValue="114480" MappingRef="OMIM">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5452048" TraitType="Disease" MappingType="XRef" MappingValue="119580" MappingRef="OMIM">
        <MedGen CUI="C4551988" Name="Blepharocheilodontic syndrome 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7568991" TraitType="Disease" MappingType="XRef" MappingValue="137215" MappingRef="OMIM">
        <MedGen CUI="C1708349" Name="Hereditary diffuse gastric adenocarcinoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5452048" TraitType="Disease" MappingType="XRef" MappingValue="608089" MappingRef="OMIM">
        <MedGen CUI="C0476089" Name="Endometrial carcinoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2693347" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0100488" MappingRef="MONDO">
        <MedGen CUI="CN311521" Name="CDH1-related diffuse gastric and lobular breast cancer syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9817076" TraitType="Disease" MappingType="XRef" MappingValue="114480" MappingRef="OMIM">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="617176" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5452048" TraitType="Disease" MappingType="XRef" MappingValue="167000" MappingRef="OMIM">
        <MedGen CUI="C1140680" Name="Ovarian cancer" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3114235" TraitType="Disease" MappingType="XRef" MappingValue="C1708349" MappingRef="MedGen">
        <MedGen CUI="C1708349" Name="Hereditary diffuse gastric adenocarcinoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5452048" TraitType="Disease" MappingType="XRef" MappingValue="137215" MappingRef="OMIM">
        <MedGen CUI="C1708349" Name="Hereditary diffuse gastric adenocarcinoma" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

